What Cencora (COR)'s Expanded Role in Kite CAR T Distribution Means For Shareholders

Simply Wall St.06-09

Cencora recently announced an agreement with Kite, a Gilead Company, to support U.S. distribution of FDA-approved CAR T-cell therapies Yescarta and Tecartus, using its specialty infrastructure to ease...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2642493089?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/24809-main-header/1756252652273","is_english":true,"pubTime":"2026-06-09 21:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642493089","market":"hk","top_or_hot":-1,"title":"What Cencora (COR)'s Expanded Role in Kite CAR T Distribution Means For Shareholders","media":"Simply Wall St.","content":"<div>\n<p>Cencora recently announced an agreement with Kite, a Gilead Company, to support U.S. distribution of FDA-approved CAR T-cell therapies Yescarta and Tecartus, using its specialty infrastructure to ease...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-cor/cencora/news/what-cencora-cors-expanded-role-in-kite-car-t-distribution-m\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Cencora (COR)'s Expanded Role in Kite CAR T Distribution Means For Shareholders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Cencora (COR)'s Expanded Role in Kite CAR T Distribution Means For Shareholders\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-09 21:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-cor/cencora/news/what-cencora-cors-expanded-role-in-kite-car-t-distribution-m><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cencora recently announced an agreement with Kite, a Gilead Company, to support U.S. distribution of FDA-approved CAR T-cell therapies Yescarta and Tecartus, using its specialty infrastructure to ease...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-cor/cencora/news/what-cencora-cors-expanded-role-in-kite-car-t-distribution-m\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1585245621.USD","symbol_name":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-cor/cencora/news/what-cencora-cors-expanded-role-in-kite-car-t-distribution-m","article_id":"2642493089","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/24809-main-header/1756252652273"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-cor/cencora/news/what-cencora-cors-expanded-role-in-kite-car-t-distribution-m","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2642493089","pubTimestamp":1781011312,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Cencora recently announced an agreement with Kite, a Gilead Company, to support U.S. distribution of FDA-approved CAR T-cell therapies Yescarta and Tecartus, using its specialty infrastructure to ease access for an expanding network of authorized treatment centers.\nThis move deepens Cencora’s presence in complex cell and gene therapies, highlighting its role in handling highly specialized, patient-specific treatments that can be operationally challenging for providers.\nNext, we’ll examine...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4585":"ETF&股票定投概念","COR":"CENCORA","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BK4084":"特种房地产投资信托","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","BK4529":"IDC概念","BK4231":"零售房地产信托","BK4022":"陆运","BK4080":"零售业房地产投资信托","BK4175":"保健护理产品经销商","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","BK4230":"旅客陆运","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","CAR":"安飞士","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","BK4588":"碎股","LU1261432733.SGD":"Fidelity World A-ACC-SGD","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","KRG":"凯特地产信托"},"translate_title":"Cencora(COR)扩大在Kite CAR T分销中的作用对股东意味着什么","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAR":1.5,"COR":1.5,"KRG":1.5},"content_text":"Cencora recently announced an agreement with Kite, a Gilead Company, to support U.S. distribution of FDA-approved CAR T-cell therapies Yescarta and Tecartus, using its specialty infrastructure to ease access for an expanding network of authorized treatment centers. This move deepens Cencora’s presence in complex cell and gene therapies, highlighting its role in handling highly specialized, patient-specific treatments that can be operationally challenging for providers. Next, we’ll examine how supporting Kite’s CAR T distribution network could influence Cencora’s investment narrative around specialty therapies and services. Uncover the next big thing with 23 elite penny stocks that balance risk and reward.AdvertisementCencora Investment Narrative RecapTo own Cencora, you have to believe in its role as a core infrastructure provider for increasingly complex, specialty-driven drug delivery. The Kite CAR T agreement fits that story, reinforcing Cencora’s capabilities in cell and gene therapy distribution. In the near term, though, the key catalyst remains execution in higher margin specialty services, while the biggest risk is ongoing margin pressure from lower fee biosimilars and generics; this announcement does not materially change either. The other development that stands out here is the appointment of Eva Boratto as CFO. Her background in large, complex healthcare organizations could matter for how Cencora balances growth investments in areas like cell and gene therapies with discipline around profitability, especially as analysts are already watching for slower earnings growth and pressure in U.S. Healthcare Solutions. But against that opportunity, investors should still pay attention to how growing biosimilar and generic volumes could weigh on Cencora’s margins and... Read the full narrative on Cencora (it's free!)Cencora's narrative projects $393.1 billion revenue and $3.4 billion earnings by 2029. This requires 6.1% yearly revenue growth and a $0.9 billion earnings increase from $2.5 billion today.Uncover how Cencora's forecasts yield a $356.83 fair value, a 30% upside to its current price.Exploring Other PerspectivesCOR 1-Year Stock Price Chart Some of the most cautious analysts were already assuming only about 4.5% annual revenue growth and earnings of roughly US$3.4 billion by 2029, and they worry that complex therapies such as CAR T could stay very service intensive and keep margins tight. Their view is clearly more pessimistic than the consensus, and this new Kite deal is exactly the kind of development that could lead you to compare these different expectations before deciding which narrative you find more reasonable.Explore 3 other fair value estimates on Cencora - why the stock might be worth just $356.83!Reach Your Own ConclusionDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Cencora research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.Our free Cencora research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cencora's overall financial health at a glance.Ready For A Different Approach?These stocks are moving-our analysis flagged them today. Act fast before the price catches up:We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.Explore 30 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.Find 47 companies with promising cash flow potential yet trading below their fair value.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642493089","isCrawlerRequest":true}